Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

From reporting gaps to hospital cost drivers to enhance digital health decision making: A machine learning-assisted analysis of national hospital data.

Digital health·2026

Same author

Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.

Molecular neurodegeneration·2026

Same author

Returning to Work After Maternity Leave: A Qualitative Study of Nurses' Experiences and Factors Influencing Their Retention.

Nursing open·2026

Same author

AI in the NICU: Considerations for Nursing Practice and Advocacy in Quality Care Outcomes for Patients and Families.

Advances in neonatal care : official journal of the National Association of Neonatal Nurses·2026

Same author

A cranberry extract stimulates procollagen I release and expression after UV radiation in a 3D skin model.

International journal of cosmetic science·2026

Same author

Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Search research articles

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Desarrollo de Fármacos

Erika N Cline¹, Elizabeth Johnson¹, Martin Kleinschmidt²

¹Acumen Pharmaceuticals, Newton, MA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association

|December 26, 2025

Resumen

Sabirnetug demuestra una selectividad superior por los oligómeros tóxicos de amiloide beta (AβOs) sobre los monómeros en la investigación de la enfermedad de Alzheimer (EA). Esta selectividad mejorada es crucial para dirigirse eficazmente a los AβOs en la EA temprana y el deterioro cognitivo leve (DCL).

Palabras clave:

Sabirnetug oligómeros de amiloide beta monómeros enfermedad de Alzheimer anticuerpos selectividad terapéutica

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Área de la Ciencia:

Neurociencia; Inmunología; Farmacología

Sus antecedentes:

Sabirnetug (ACU193) es un anticuerpo monoclonal dirigido a oligómeros solubles tóxicos de amiloide beta (AβOs).; Su eficacia se está investigando para el deterioro cognitivo leve (DCL) y la enfermedad de Alzheimer (EA) temprana.; La alta selectividad por AβOs sobre monómeros es clave debido a la abundancia de monómeros en DCL/EA.

Objetivo del estudio:

Comparar las afinidades de unión y la selectividad de sabirnetug frente a otros anticuerpos dirigidos a Aβ.; Evaluar la ventaja terapéutica potencial de sabirnetug en la orientación de AβOs en la EA.

Principales métodos:

Producción recombinante de lecanemab, aducanumab y donanemab.; Se utilizó resonancia de plasmón de superficie (SPR) para determinar la cinética de unión a oligómeros y monómeros de Aβ.; Comparación de las afinidades de unión (K_D) y las relaciones de selectividad.

Principales resultados:

Sabirnetug exhibió las mayores afinidades de unión a oligómeros de Aβ (ADDLs, oligómeros de Aβ_1-42).; Sabirnetug demostró una afinidad significativamente menor por el Aβ_1-40 monomérico, lo que resultó en una alta selectividad.; Aducanumab y donanemab mostraron una menor selectividad de AβOs sobre monómeros.

Conclusiones:

Sabirnetug muestra una selectividad superior por AβOs sobre Aβ monomérico en comparación con los anticuerpos probados.; La alta selectividad posiciona favorablemente a sabirnetug para la orientación de AβOs en DCL/EA.; La investigación adicional en ALTITUDE-AD (NCT06335173) está en curso.